Congrats! Australian Patent for GM-XAN003 Granted – A New Breakthrough in Psoriasis Treatment!

The innovative drug GM-XAN003, developed by XanthoBio for the treatment of psoriasis, was granted an Australian in April 2025.

(Patent name: Use of Mangosteen Fruit Shell Extract in the Preparation of a Medication for Treating Psoriasis; Patent No. 2021472146)

Psoriasis is a chronic, relapsing, immune-mediated skin disorder that significantly impacts patients’ quality of life due to symptoms such as erythema, scaling, and skin thickening.

While several treatment options exist, many challenges remain. Biologics are costly, while mild to moderate cases are often managed with steroids.However, efficacy and safety limitations persist, underscoring the urgent need for innovative treatments.

The core active ingredient in GM-XAN003 is a proprietary extract derived from the mangosteen shell. Leveraging its scientifically backed anti-inflammatory and immune-modulating properties, GM-XAN003 represents a novel and promising therapeutic option for psoriasis patients.The granting of this patent not only recognizes XanthoBio’s innovative capabilities in biotechnology research but also lays a critical foundation for future clinical progress.
XanthoBio remains committed to advancing the clinical research and commercialization of GM-XAN003, striving to provide a safer, more effective treatment option for psoriasis patients worldwide.